04 · Five things to know · 04

Regeneron’s Livsayis, an RNAi drug discovered by Alnylam, was approved for generalized myasthenia gravis

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 1 min read

Know it

What happened

Alnylam said on 11.19 that FDA approved Livsayis (cemdisiran), from its collaborator Regeneron, for adults with generalized myasthenia gravis who test positive for antibodies to the acetylcholine receptor. It silences C5, a complement protein, and is given under the skin four times a year. Alnylam calls it the first RNAi therapy for the disease and the seventh approved drug discovered by Alnylam, and it receives a $25M milestone and royalties of up to 15%. FDA’s novel approvals list dates the approval itself to 11.18. Claim

C5 blockade is already used in this disease; dosing four times a year is the difference the companies stress. We did not read the label. Analysis

Sources

Also in Five things to know

Bookmarks need a Mind Club sign-in. How sign-in works

Read it in Five things to know